Leonid Reyfman, MD
Interventional Pain Medicine · Brooklyn, NYNPI 1659440394
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Milestone Scientific Inc. at 57.9% of the total. Reporting peaked in 2023 at $9,612 and has fallen 81.3% since, to $1,796 in 2025.
Across 146 payments — averaging $106.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Milestone Scientific Inc.$9K
- Medtronic$2K
- AbbVie$742
- Abbott$303
- Biohaven Pharmaceutical Holding Company Ltd.$285
- Relievant Medsystems, Inc.$243
- plus $3K from 31 others
What the payments were for
- Consulting fees$9,00058%
- Travel & lodging$2432%
- Food & beverage$6,16640%
- Other$1291%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Milestone Scientific Inc. | 1 | $9,000 |
| Medtronic(2 entities) | 22 | $2,228 |
| AbbVie | 31 | $742 |
| Abbott | 3 | $303 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $285 |
| Relievant Medsystems, Inc. | 1 | $243 |
| Boston Scientific | 2 | $234 |
| Scilex Pharmaceuticals Inc. | 11 | $224 |
| Saluda Medical Americas, Inc. | 3 | $223 |
| Globus Medical | 1 | $173 |
| Nevro Corp. | 1 | $150 |
| Alkermes, Inc. | 2 | $141 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $137 |
| Aesculap, Inc. | 1 | $129 |
| MML US, Inc. | 2 | $125 |
| Stimwave Technologies Incorporated | 1 | $124 |
| Amgen(2 entities) | 6 | $112 |
| Eisai Inc. | 4 | $110 |
| Biodelivery Sciences International, Inc. | 6 | $91 |
| Si-bone, Inc. | 3 | $87 |
| Pfizer | 4 | $77 |
| Vertex | 3 | $74 |
| Collegium Pharmaceutical, Inc. | 3 | $56 |
| Biohaven Pharmaceuticals, Inc. | 3 | $49 |
| Johnson & Johnson | 2 | $45 |
| Neuronetics, Inc. | 1 | $44 |
| Valinor Pharma, LLC | 2 | $42 |
| Pacira Therapeutics, Inc. | 2 | $42 |
| Spinefrontier, Inc. | 1 | $40 |
| Curonix LLC | 1 | $36 |
| Forte Bio-pharma LLC | 1 | $30 |
| Almatica Pharma LLC | 1 | $29 |
| Epimed International, Inc | 1 | $29 |
| Redhill Biopharma Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| Lundbeck LLC | 1 | $21 |
| Indivior Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COMPUFLO EPIDURAL$9,000
- INTELLIS ADAPTIVESTIM$1,441
- Intracept$486
- Axium INS DRG IPG$191
- Senza$173
- SYNCHROMED$165
- Evoke$164
- Senza Spinal Cord Stimulation System$150
- INCEPTIV$146
- Superion Indirect Decompression System$142
- StimQ Receiver Stimulator Kit Channel A US w Receiver$124
- StimQ Freedom-4A Receiver Kit Channel A US w/ Receiver$124
- StimQ Freedom 8A Receiver Kit Channel A US w Receiver$124
- Freedom 4A Receiver Kit Channel A US w Receiver$124
- Freedom 8A Receiver Kit Channel A US w Receiver$124
- NURTEC ODT$122
- VIVITROL$120
- ReActiv8$107
How this compares
$15,537 in reported general payments places this provider in the 80th percentile of 132 interventional pain medicine providers in New York.
See all interventional pain medicine providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 17 | $2,886 |
| Tizanidine Hcl | 18 | $89 |
| Meloxicam | 11 | $48 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Brooklyn
- Dmitriy DvoskinBrooklyn$6K
- Deepali GuptaBrooklyn$5K
- Corey HunterNew York$446K
- Neel MehtaNew York$432K
- Hemant KaliaRochester$179K
- Martin FerrilloAlbany$164K
- George ChaseKew Gardens$102K
- Kimberly SackheimNew York$102K
- Suelane OuroNew York$68K
- Gerard DegregorisNew York$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.